Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
A retinal implant about 2 by 2 millimeters has helped some people with advanced dry age-related macular degeneration perceive useful central visual information. But it does not restore ordinary eyesight, and it is not a treatment for blindness in general. The system pairs a 378-pixel chip beneath the retina with camera-equipped glasses, image processing and visual rehabilitation.
What the “grain-of-rice” chip actually does
The headline most closely describes PRIMA, a wireless photovoltaic retinal implant developed by Science Corporation. The company describes the implant as roughly 2 by 2 millimeters and containing 378 pixels. “Grain of rice” is a rough visual comparison, not its engineering specification.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
CafePress Retinal Implant, Artwork Round 4" MDF Holiday Ornament | $8.99 | Buy on Amazon |
PRIMA is designed for people whose central vision has been severely damaged by geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). In this condition, photoreceptors in the macula—the part of the retina used for detailed central vision—are lost. Some inner retinal cells and the downstream visual pathway may remain functional, giving electrical stimulation a route to the brain.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11The chip does not act as a miniature camera or work by itself. The full system uses glasses and external equipment:
#1 Best Overall
- MEASUREMENTS: 4" MDF Wood Design - Lightweight yet durable ornament featuring professionally printed artwork that brings elegance to any holiday display
- VERSATILE DECORATION: Includes a festive red ribbon for traditional tree hanging, but also stands beautifully on mantels, shelves, or office desks year-round
- PREMIUM GIFT-READY QUALITY: Makes a thoughtful, personalized present that shows extra care compared to standard holiday gifts
- MEMORY MAKER: Perfect keepsake for commemorating special moments like Baby's First Christmas, weddings, anniversaries, or family milestones
- TIMELESS KEEPSAKE: Creates lasting holiday traditions as it's lovingly unpacked and displayed year after year, becoming part of your family's cherished memories
- A camera on the glasses captures the scene.
- An external processor converts the image into a stimulation pattern.
- A projector in the glasses sends coded near-infrared light into the eye.
- The implant’s photovoltaic pixels convert that light into electrical pulses.
- The pulses stimulate surviving retinal cells, which send signals through the optic nerve to the brain.
- With fitting and rehabilitation, the user learns to interpret the resulting artificial visual perceptions.
The implant is placed beneath the retina. It is powered by the projected light rather than by a battery implanted in the eye. The glasses, processor, projector and training are essential parts of the treatment, not optional accessories. Science’s PRIMA overview and its patient manual describe the components and intended use.
What the clinical study found
A multicenter study published in the New England Journal of Medicine implanted PRIMA in 38 people with severe central vision loss from geographic atrophy caused by dry AMD. At 12 months, 32 participants were assessed; 26 of them, or 81%, had a clinically meaningful improvement in visual acuity. The study’s estimate accounting statistically for missing participants was an 80% response rate. Participants were tested with and without the PRIMA glasses.
That result is promising, but it needs context. The study was prospective, open-label, single-group and baseline-controlled—not a randomized controlled trial. It was also small and enrolled a narrowly selected group. The 81% figure refers to the 32 people assessed at 12 months, not to every person with blindness or everyone who might receive an implant.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →The trial also reported 26 serious adverse events in 19 participants. Twenty-one events occurred within two months of surgery, and most resolved within two months of onset. Natural peripheral visual acuity was not meaningfully reduced in the study, but the adverse events underline that implantation is major eye surgery, not a risk-free fitting. See the published clinical study for its methods and results.
What patients may see—and what “restored sight” means
PRIMA aims to provide artificial central vision that can supplement a person’s remaining natural peripheral vision. Some participants learned to detect and interpret visual information such as shapes, letters, numbers, words and objects. Science says 84% of participants reported being able to read letters, numbers or words at home with PRIMA at 12 months. That is a company-reported result, and reading performance involved the complete system, including digital zoom and contrast enhancement, as well as rehabilitation.
These results do not mean the implant recreates normal vision. The system does not provide natural color vision or normal stereoscopic depth perception, and it does not restore a full natural field of view. Artificial visual signals can require practice to interpret; recognizing a pattern is not the same as instantly seeing a complex scene as a person with healthy sight would.
How much benefit an individual gets can vary. In an earlier, very small feasibility study, average visual acuity without zoom was around 20/500; some patients achieved larger improvements on zoom-assisted tests. The newer study’s results likewise involve the glasses-based system, so they should not be described as unaided recovery of normal eyesight. No single acuity figure guarantees what a future patient will be able to read or do.
Who might qualify—and who should not assume they do
The evidence and intended use focus on adults with advanced geographic atrophy from dry AMD, severe central vision loss involving the fovea, and enough surviving inner-retinal function and optic-nerve function to carry signals to the brain. An eye specialist would need to assess the cause and location of vision loss, the state of the remaining visual pathway and other clinical factors.
“Blindness” describes many different conditions. Damage to the optic nerve, as can occur in glaucoma, may interrupt the pathway the implant depends on. Diabetic retinopathy, trauma or injury to the visual cortex involve different problems and are not established indications for PRIMA. Research in other retinal diseases does not make those uses approved or proven. The implant should not be presented as a universal solution for people who cannot see.
Risks, equipment and day-to-day limitations
PRIMA involves vitreoretinal surgery and the risks that can accompany eye surgery, including retinal or choroidal complications, infection, inflammation, bleeding or retinal detachment. The clinical study’s serious-adverse-event record deserves attention alongside its visual-acuity results. After surgery, patients need device fitting and visual rehabilitation; the result may be limited or variable.
Users also depend on external glasses and equipment. The PRIMA patient manual describes the system as a complementary aid and warns users not to rely on it alone for mobility. Canes, guide dogs and other mobility tools may still be needed. Anyone considering the technology should discuss both the potential visual benefit and surgical, practical and rehabilitation burdens with a retinal specialist.
PRIMA, Argus II and Orion are different devices
| System | Where it is implanted | Target or approach | Status |
|---|---|---|---|
| PRIMA | Beneath the retina | Photovoltaic implant for central vision loss from geographic atrophy associated with dry AMD | Science says it is approved in Europe and not approved outside Europe; it is not commercially available outside the EU/EEA. |
| Argus II | On the retina | Camera and external processor sent signals to an electrode array that stimulated retinal cells; its historical indication was severe retinitis pigmentosa (RP). | Received U.S. FDA authorization under a Humanitarian Device Exemption for a narrow indication, but has been discontinued and is no longer available. |
| Orion | On the visual cortex in the brain | An investigational cortical prosthesis intended to bypass the eye | Investigational; not FDA-approved. |
These devices are not interchangeable. PRIMA targets the retina from beneath it; Argus II used a different retinal electrode design; Orion aims to stimulate the brain’s visual cortex. FDA authorization for Argus II does not mean PRIMA is FDA-approved. The FDA’s Argus II HDE record, Cortigent’s Argus II page and its Orion page distinguish their indications and status.
Availability in Europe and the United States
As of August 18, 2026, Science says PRIMA is approved in Europe but has no regulatory approval outside Europe and is not commercially available outside the EU/EEA. It is therefore not a treatment that a U.S. patient can simply buy. The official materials reviewed do not give a public U.S. consumer price. Availability and eligibility depend on jurisdiction and clinical circumstances; a retinal specialist is the appropriate person to discuss options and legitimate study pathways.
Argus II is not a current alternative: although it once had a narrow FDA authorization for adults with severe-to-profound RP and bare-light or no-light perception in both eyes who met additional criteria, the device has been discontinued. Its historical prices are not current prices for a treatment available today. Do not confuse historical approval with present availability, or treat sellers of unapproved implants as legitimate access routes.
For official information, patients can review the PRIMA patient registry and the PRIMA technology and eligibility page, then discuss their diagnosis with a retinal specialist. A registry or company page is not a guarantee of eligibility or treatment.
Recommended Free Tools
The realistic takeaway
PRIMA is a significant step in retinal prosthetics: in a selected group with severe central vision loss from geographic atrophy, a tiny implant paired with glasses helped many assessed participants gain measurable artificial central visual function. But the outcome is not normal eyesight, the treatment carries surgical and practical burdens, and the current evidence does not support claims that it can restore sight to all blind people. It is a specialized medical technology, with European availability and no U.S. commercial access as of August 18, 2026.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
